Contineum Therapeutics, Inc.于2009年作为Versense Pharmaceuticals, Inc. (Versense)在特拉华州注册成立。2023年11月，公司更名为Contineum Therapeutics, Inc. 该公司是一家临床阶段的生物制药公司，专注于发现和开发具有高未满足需求的NI&I适应症的新型口服小分子疗法。他们针对与特定临床损伤相关的生物学途径，他们认为这些途径一旦得到调节，将明显改变疾病的进程。
董事
名称
职位
Carmine Stengone
Chief Executive Officer, President and Director
Evert Schimmelpennink
Chair of the Board
Clare R. Ozawa
Director
Lori M. Lyons Williams
Director
Olivia Ware
Director
Stefan M. Larson
Director
Todd R. Brady
Director
股东
名称
职位
Carmine Stengone
Chief Executive Officer, President and Director
Peter T. Slover
Chief Financial Officer
Stephen L. Huhn
Chief Medical Officer and Senior Vice President, Clinical Development